Vaxil BioTherapeutics is a clinical-stage company developing immunotherapeutic products, including long peptide vaccines and antibodies to treat cancer and infectious diseases. Vaxils products are derived from its fully owned proprietary technology, VaxHit, which uses the signal peptide domains in selected targets as core antigens. The companys lead product, ImMucin, has received EMA and FDA orphan drug designation for the treatment of multiple myeloma (MM) cancer. ImMucin has successfully completed a phase 1/2 clinical trial in 15 MM patients demonstrating a high safety profile and preliminary evidence for clinical efficacy. Vaxil is currently performing an additional phase 1/2 study with ImMucin in metastatic breast cancer patients being treated with first-line hormonal therapy. Vaxil has also isolated SPmAb-2.1 and SPmAb-6, which are anti-MUC1 SP antibodies with therapeutic and diagnostic properties that are potentially superior to other MUC1 antibodies. Vaxil further validated its VaxHit technology for anti-infective indications and isolated MTBuVax, a vaccine against mycobacterium tuberculosis that is currently in preclinical animal studies. Vaxil BioTherapeutics is a fully owned subsidiary of Vaxil Bio.